Hematology/Oncology · Fountain Valley, CA
NPI
1639238371
Since 2006
Specialty
Hematology/Oncology
Code 174400000X
Group practices
2
Medicare group memberships
Hospitals
3
Hospital affiliations
11180 Warner Ave Ste 351
Fountain Valley, CA, 92708
Phone (714) 698-0300
Groups this clinician bills Medicare through
Medicare paid, 2024
$2.2M
97,318 services
Medicare patients, 2024
318
Average age 73
Drug cost, 2024
$4.4M
1,242 prescriptions
Company payments, 2025
$8,490
From 58 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Peyman Salimi-Tari was code J9271 (injection, pembrolizumab, 1 mg), 19,007 times for 12 patients. In total Peyman Salimi-Tari billed 97,318 services in 91 codes, and Medicare paid $2.2M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2019-05-15.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J9271 Injection, pembrolizumab, 1 mg | Office | 19,007 | 12 | $44.70 | $850K |
| J0897 Injection, denosumab, 1 mg | Office | 3,244 | 16 | $20.97 | $68K |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 2,348 | 25 | $0.09 | $209 |
| J2405 Injection, ondansetron hydrochloride, per 1 mg | Office | 1,604 | 13 | $0.07 | $117 |
| J1437 Injection, ferric derisomaltose, 10 mg | Office | 1,500 | 11 | $16.11 | $24K |
| 99214 Office E&M - Established | Office | 529 | 233 | $104.46 | $55K |
| 96413 Chemotherapy Administration | Office | 274 | 31 | $115.36 | $32K |
| 99215 Office E&M - Established | Office | 217 | 101 | $139.96 | $30K |
| 96367 Intravenous Infusion, Hydration | Office | 208 | 29 | $25.36 | $5,276 |
| 96372 Injection Administration | Office | 168 | 31 | $12.47 | $2,096 |
| J1200 Injection, diphenhydramine hcl, up to 50 mg | Office | 156 | 26 | $0.65 | $101 |
| 96127 Behavioral Health Services | Office | 120 | 108 | $3.94 | $473 |
| J3489 Injection, zoledronic acid, 1 mg | Office | 107 | 19 | $4.85 | $519 |
| 36415 Venipuncture Blood Collection | Office | 105 | 56 | $8.61 | $904 |
| 96417 Chemotherapy Administration | Office | 102 | 15 | $56.84 | $5,797 |
By year: 2022 $1.0M for 38,175 services; 2023 $1.1M for 54,292 services; 2024 $2.2M for 97,318 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 105 | 56 | $8.61 | $904 |
Medicare prescription drug claims, 2024
In 2024, the drug Peyman Salimi-Tari prescribed most often to Medicare patients was Neulasta (Pegfilgrastim), with 72 prescriptions and refills. In total Peyman Salimi-Tari wrote 1,242 Medicare prescriptions that cost $4.4M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Neulasta Pegfilgrastim | 72 | 72 | 14 | $458K |
| Diphenhydramine Hcl Generic | 66 | 72 | 20 | $134 |
| Dexamethasone Sodium Phosphate Generic | 65 | 65 | 21 | $283 |
| Famotidine Famotidine/Pf | 53 | 58 | 18 | $98.81 |
| Docetaxel Generic | 39 | 39 | Under 11 | $8,405 |
| Letrozole Generic | 37 | 83 | 18 | $699 |
| Ondansetron Hcl Ondansetron Hcl/Pf | 36 | 36 | Under 11 | $149 |
| Palonosetron Hcl Generic | 36 | 36 | 15 | $1,722 |
| Orgovyx Relugolix | 30 | 30 | Under 11 | $72K |
| Carboplatin Generic | 25 | 25 | Under 11 | $1,184 |
| Tagrisso Osimertinib Mesylate | 25 | 25 | Under 11 | $430K |
| Prednisone Generic | 24 | 35 | Under 11 | $94.85 |
| Abiraterone Acetate Generic | 23 | 25 | Under 11 | $87K |
| Keytruda Pembrolizumab | 23 | 23 | Under 11 | $259K |
| Lupron Depot Leuprolide Acetate | 22 | 62 | Under 11 | $117K |
Brand drugs: 552 claims; generic drugs: 690 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Peyman Salimi-Tari $8,490 ($8,490 in general payments such as food, travel and fees) from 58 companies. The largest payer was Abbvie Inc. with $514.
| Company | Payments | Amount |
|---|---|---|
| Abbvie Inc. ABBV | 27 | $514 |
| AstraZeneca Pharmaceuticals LP AZN | 20 | $498 |
| Caris MPI, Inc. | 10 | $458 |
| Janssen Biotech, Inc. JNJ | 15 | $343 |
| GlaxoSmithKline, LLC. GSK | 15 | $320 |
| Novartis Pharmaceuticals Corporation NVS | 13 | $313 |
| Eisai Inc. 4523.T | 11 | $280 |
| E.R. Squibb & Sons, L.L.C. BMY | 17 | $279 |
| Incyte Corporation INCY | 10 | $269 |
| Daiichi Sankyo Inc. 4568.T | 11 | $262 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.